[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341134-105":59,"doc-detail-341134-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","checkpoint-inhibitor-expressing-lentiviral-vaccine-suppresses-tumor-growth-in-preclinical-cancer-models-original-research","Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models - Original research","","Background: While immunotherapy is highly effective for some cancers, weak immune responses to tumor antigens cause failure in others, and tumor resistance to checkpoint inhibitors may involve T cell exhaustion from checkpoint activation. Methods: Lentiviral vectors expressing T cell epitopes from an introduced antigen (ovalbumin) or an endogenous antigen (Trp1) were engineered with CD40L to mature dendritic cells and a PD-1 microbody to block checkpoint activation. Results: Vaccination expanded functional antigen-specific cytolytic CD8 T cells that infiltrated and suppressed tumor growth; adoptive transfer and direct vector injection showed CD8-mediated effects. Conclusions: The study supports therapeutic vaccination inducing tumor antigen-specific CD8 T cells alongside a vector-encoded checkpoint inhibitor to control checkpoint-resistant tumors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/checkpoint-inhibitor-expressing-lentiviral-vaccine-suppresses-tumor-growth-in-preclinical-cancer-models-original-research/341134/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/checkpoint-inhibitor-expressing-lentiviral-vaccine-suppresses-tumor-growth-in-preclinical-cancer-models-original-research/341134.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in cancer immunotherapy?","Question",{"text":112,"@type":113},"The study targets cases where immune responses to tumor antigens are weak, leading to treatment failure, and where tumors resist checkpoint inhibitor therapy due to T cell exhaustion driven by checkpoint activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the lentiviral vectors engineered in this research?",{"text":117,"@type":113},"The vectors expressed T cell epitopes from ovalbumin or Trp1, coexpressed CD40L to mature dendritic cells, and included a soluble PD-1 microbody designed to prevent checkpoint activation.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings on tumor growth suppression?",{"text":121,"@type":113},"Vaccination expanded CD8 T cells that infiltrated tumors and suppressed growth. CD40L and the PD-1 microbody increased the magnitude of suppression, and adoptive transfer showed the effect was mediated by CD8 T cells; direct vector injection without ex vivo DC transduction was also effective.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341134,1790325148,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Open access Original research  \n Checkpoint inhibitor-expressing  \nlentiviral vaccine suppresses tumor growth in preclinical cancer models  \nTakuya Tada  ,1 Thomas D Norton,1,2 Rebecca Leibowitz,1 Nathaniel R Landau  1  \nTo cite: Tada T, Norton TD, Leibowitz R, et al. Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical  \ncancer models. Journal for ImmunoTherapy of Cancer 2024;12:e008761 . doi:10 . 1136/ jitc-2023-008761  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2023-008761](jitc-2023-008761)) .  \nTT and TDN contributed equally. Accepted 31 March 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA  \n2Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA  \nCorrespondence to  \nDr Nathaniel R Landau;  \n[nathaniel.landau@med.nyu.edu](nathaniel.landau@med.nyu.edu)  \nABSTRACT  \nBackground While immunotherapy has been highly successful for the treatment of some cancers, for others, the immune response to tumor antigens is weak leading to treatment failure. The resistance of tumors to checkpoint inhibitor therapy may be caused by T cell exhaustion resulting from checkpoint activation.  \nMethods In this study, lentiviral vectors that expressed T cell epitopes of an experimentally introduced tumor antigen, ovalbumin, or the endogenous tumor antigen, Trp1 were developed. The vectors coexpressed CD40 ligand (CD40L), which served to mature the dendritic cells (DCs), and a soluble programmed cell death protein 1 (PD-1) microbody to prevent checkpoint activation. Vaccination of mice bearing B16 .OVA melanomas with vector-transduced DCs induced the proliferation and activation of functional, antigen-specific, cytolytic CD8 T cells.  \nResults Vaccination induced the expansion of CD8 T cells that infiltrated the tumors to suppress tumor growth. Vector-encoded CD40L and PD-1 microbody increased the extent of tumor growth suppression. Adoptive transfer demonstrated that the effect was mediated by CD8 T cells. Direct injection of the vector, without the need for ex vivo transduction of DCs, was also effective.  \nConclusions This study suggests that therapeutic vaccination that induces tumor antigen-specific CD8 T cells coupled with a vector-expressed checkpoint inhibitor can be an effective means to suppress the growth of tumors that are resistant to conventional immunotherapy.  \nINTRODUCTION  \nCancer immunotherapy has seen a major advance with the development of checkpoint inhibitors for the treatment of several types of cancer including melanoma, non-small cell lung cancer, bladder cancer, and other solid tumors.1–4 While checkpoint immunotherapy is successful in many patients, the success rate remains 30%–50% for melanoma, nonsmall cell lung cancer, and bladder cancer.5 Several factors are thought to influence the effectiveness of immunotherapy. A high mutational burden in the tumor is associated with better responses due to the expression of  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Cancer can be controlled by T cells that recognize tumor antigens. Checkpoint immunotherapy increases the effectiveness of T cells in controlling cancer by restoring function to exhausted T cells. Ina significant fraction of patients, immunotherapy isnot successful, most likely because there are not a sufficient number of T cells that target tumor antigens. Dendritic cells present tumor antigen epitopesto T cells on major histocompatibility complex class I but may not activate a sufficient number of antitumor T cells. Therapeutic dendritic cell vaccines that present tumor antigen to T cells have seen some clinical success. Lentiviral vectors provide a means to ","cbCainDg56OkeuMb","https://ap.wps.com/l/cbCainDg56OkeuMb","pdf",3152842,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Therapeutic vaccination and checkpoint inhibitors","[{\"question\":\"What problem does the study address in cancer immunotherapy?\",\"answer\":\"The study targets cases where immune responses to tumor antigens are weak, leading to treatment failure, and where tumors resist checkpoint inhibitor therapy due to T cell exhaustion driven by checkpoint activation.\"},{\"question\":\"How were the lentiviral vectors engineered in this research?\",\"answer\":\"The vectors expressed T cell epitopes from ovalbumin or Trp1, coexpressed CD40L to mature dendritic cells, and included a soluble PD-1 microbody designed to prevent checkpoint activation.\"},{\"question\":\"What were the key findings on tumor growth suppression?\",\"answer\":\"Vaccination expanded CD8 T cells that infiltrated tumors and suppressed growth. CD40L and the PD-1 microbody increased the magnitude of suppression, and adoptive transfer showed the effect was mediated by CD8 T cells; direct vector injection without ex vivo DC transduction was also effective.\"}]","Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models - Original research | PDF",1790040511,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba815b7cbdca4ae7ac3f4625bf9c456e.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a9a43608bf1aaffe916a413d475d308.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80443ff5f265987964864e52328399df.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db7b0430c8186b8184988f3ef76c38c8.webp",980,1306]